FOURTH EDITION
Edited by
Drew Provan MD FRCP FRCPath
Emeritus Reader in Autoimmune Haematology
Department of Haematology
Barts and The London School of Medicine and Dentistry
Queen Mary University of London, UK
John G. Gribben MD DSc FRCP FRCPath FMedSci
Professor of Medical Oncology
Barts Cancer Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London, UK
This edition first published 2020
© 2020 by John Wiley & Sons
Edition History [3rd edition, 2010]
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Drew Provan to be identified as the author of editorial in this work has been asserted in accordance with law.
Registered Office(s)
John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial Office
9600 Garsington Road, Oxford, OX4 2DQ, UK
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty
The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging-in-Publication Data
Names: Provan, Drew, editor. | Gribben, John editor.
Title: Molecular hematology / edited by Drew Provan, John G. Gribben.
Description: Fourth edition. | Hoboken, NJ : Wiley-Blackwell, 2020. |
Includes bibliographical references and index.
Identifiers: LCCN 2019034376 (print) | LCCN 2019034377 (ebook) | ISBN 9781119252870 (hardback) | ISBN 9781119252955 (adobe pdf) | ISBN 9781119252931 (epub)
Subjects: MESH: Hematologic Diseases | Molecular Biology–methods
Classification: LCC RC636 (print) | LCC RC636 (ebook) | NLM WH 120 | DDC 616.1/5–dc23
LC record available at https://lccn.loc.gov/2019034376
LC ebook record available at https://lccn.loc.gov/2019034377
Cover Design: Wiley
Cover Image: © JUAN GAERTNER/SCIENCE PHOTO LIBRARY/Getty Images
We would like to dedicate this book to two people: our dear friend and colleague, Professor Sir David Weatherall, who sadly passed away on 8 December 2018. He was truly a pioneer of molecular biology and was the first physician scientist to use molecular techniques to study hematological disease. We will all miss him very much.
In addition, we would like to dedicate the book to Val Provan. Always in our thoughts and much missed.
Hematology is a fast-moving discipline with innovation both diagnostically and therapeutically. In the 19 years since the first edition of Molecular Hematology was published, many advances have been made. Molecular techniques have helped explain the basis of many diseases, starting initially with red cell disorders and hemostasis. However, thanks to the use of molecular biology we can now diagnose and stratify patients with diseases such as leukemia, myeloma, myeloproliferative neoplasms, and others. Such advances in technology have not only helped explain the underlying basis of the diseases, but have also provided targets for treatment.
The world of red cells started the whole specialty of molecular medicine and, using molecular biology techniques, many of the phenotypic features of red cell disorders have been explained. This is discussed eloquently by the late Professor Sir David Weatherall at the beginning of the book. Other non-malignant areas which have been updated include the Functions of Blood Group Antigens, von Willebrand Disease, and Platelet Disorders.
Undoubtedly, hemato-oncology has seen the biggest explosion in terms of understanding the molecular basis of diseases such as leukemias, lymphomas, the myeloproliferative neoplasms, myeloma, and myelodysplastic syndromes. The huge array of biological markers makes stratification and treatment much more sophisticated than ever before. All the chapters dealing with malignant blood diseases have been thoroughly revised and brought up to date.
However, despite the growing complexity in terms of pathogenesis, diagnosis, and management of patients with blood diseases, the ethos of the book remains the same – namely, to provide a succinct account of the molecular biology of hematological disease written at a level where it should be of benefit to both the seasoned molecular biologist and the practicing clinician alike. We have retained the original structure for the chapters, high-quality artwork, and Further Reading sections in order to make the book visually appealing and relevant to modern hematology practice.
We very much hope you enjoy this edition and, as always, we welcome any comments or suggestions from readers, which we will attempt to incorporate into the next edition.
Drew Provan
John Gribben
We would like to express thanks to Claire Bonnett, Publisher, and Deirdre Barry, Senior Editorial Assistant, for their help with this work.